Baker Ellis Asset Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $303K | Hold |
3,350
| – | – | 0.03% | 210 |
|
|
2026
Q1 | $268K | Hold |
3,350
| – | – | 0.03% | 220 |
|
|
2025
Q4 | $286K | Hold |
3,350
| – | – | 0.03% | 214 |
|
|
2025
Q3 | $261K | Hold |
3,350
| – | – | 0.03% | 216 |
|
|
2025
Q2 | $262K | Hold |
3,350
| – | – | 0.04% | 196 |
|
|
2025
Q1 | $243K | Hold |
3,350
| – | – | 0.04% | 204 |
|
|
2024
Q4 | $248K | Hold |
3,350
| – | – | 0.04% | 191 |
|
|
2024
Q3 | $221K | Sell |
3,350
-150
| -4% | -$10.9K | 0.03% | 208 |
|
|
2024
Q2 | $323K | Hold |
3,500
| – | – | 0.05% | 171 |
|
|
2024
Q1 | $334K | Hold |
3,500
| – | – | 0.05% | 169 |
|
|
2023
Q4 | $267K | Hold |
3,500
| – | – | 0.04% | 182 |
|
|
2023
Q3 | $242K | Hold |
3,500
| – | – | 0.04% | 179 |
|
|
2023
Q2 | $330K | Hold |
3,500
| – | – | 0.06% | 157 |
|
|
2023
Q1 | $290K | Sell |
3,500
-809
| -19% | -$63.6K | 0.05% | 165 |
|
|
2022
Q4 | $321K | Hold |
4,309
| – | – | 0.06% | 154 |
|
|
2022
Q3 | $356K | Hold |
4,309
| – | – | 0.08% | 148 |
|
|
2022
Q2 | $410K | Hold |
4,309
| – | – | 0.09% | 141 |
|
|
2022
Q1 | $507K | Hold |
4,309
| – | – | 0.09% | 133 |
|
|
2021
Q4 | $558K | Hold |
4,309
| – | – | 0.1% | 129 |
|
|
2021
Q3 | $469K | Sell |
4,309
-100
| -2% | -$11.4K | 0.09% | 134 |
|
|
2021
Q2 | $457K | Sell |
4,409
-58
| -1% | -$5.47K | 0.09% | 132 |
|
|
2021
Q1 | $374K | Hold |
4,467
| – | – | 0.08% | 139 |
|
|
2020
Q4 | $408K | Hold |
4,467
| – | – | 0.1% | 125 |
|
|
2020
Q3 | $357K | Hold |
4,467
| – | – | 0.1% | 120 |
|
|
2020
Q2 | $309K | Hold |
4,467
| – | – | 0.09% | 131 |
|
|
2020
Q1 | $281K | Hold |
4,467
| – | – | 0.1% | 125 |
|
|
2019
Q4 | $347K | Hold |
4,467
| – | – | 0.1% | 128 |
|
|
2019
Q3 | $327K | Hold |
4,467
| – | – | 0.09% | 142 |
|
|
2019
Q2 | $275K | Sell |
4,467
-333
| -7% | -$20.1K | 0.07% | 153 |
|
|
2019
Q1 | $306K | Hold |
4,800
| – | – | 0.09% | 141 |
|
|
2018
Q4 | $245K | Sell |
4,800
-300
| -6% | -$15.2K | 0.07% | 155 |
|
|
2018
Q3 | $296K | Hold |
5,100
| – | – | 0.08% | 162 |
|
|
2018
Q2 | $247K | Hold |
5,100
| – | – | 0.07% | 169 |
|
|
2018
Q1 | $237K | Sell |
5,100
-150
| -3% | -$6.51K | 0.06% | 174 |
|
|
2017
Q4 | $197K | Hold |
5,250
| – | – | 0.05% | 186 |
|
|
2017
Q3 | $191K | Sell |
5,250
-600
| -10% | -$22.9K | 0.05% | 192 |
|
|
2017
Q2 | $231K | Sell |
5,850
-150
| -3% | -$5.47K | 0.06% | 182 |
|
|
2017
Q1 | $188K | Hold |
6,000
| – | – | 0.05% | 191 |
|
|
2016
Q4 | $187K | Hold |
6,000
| – | – | 0.05% | 199 |
|
|
2016
Q3 | $241K | Hold |
6,000
| – | – | 0.07% | 182 |
|
|
2016
Q2 | $199K | Hold |
6,000
| – | – | 0.06% | 187 |
|
|
2016
Q1 | $176K | Hold |
6,000
| – | – | 0.06% | 195 |
|
|
2015
Q4 | $158K | Hold |
6,000
| – | – | 0.05% | 204 |
|
|
2015
Q3 | $142K | Hold |
6,000
| – | – | 0.05% | 213 |
|
|
2015
Q2 | $142K | Hold |
6,000
| – | – | 0.05% | 224 |
|
|
2015
Q1 | $142K | Hold |
6,000
| – | – | 0.05% | 229 |
|
|
2014
Q4 | $127K | Buy |
+6,000
| New | +$121K | 0.04% | 225 |
|
Other funds holding EW
Baker Ellis Asset Management's EW Position: Q2 2026 in Review
Baker Ellis Asset Management held its Edwards Lifesciences (EW) position steady in Q2 2026 at 3,350 shares worth $303K. The position accounts for 0.03% of the portfolio, ranked #210.
Baker Ellis Asset Management first reported a position in EW in Q4 2014 and has held it in 47 quarters since. The position peaked at $558K in Q4 2021. 1,327 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Baker Ellis Asset Management held 3,350 shares of Edwards Lifesciences worth $303K as of Q2 2026.
- Baker Ellis Asset Management left its Edwards Lifesciences share count unchanged in Q2 2026.
- Edwards Lifesciences made up 0.03% of Baker Ellis Asset Management's portfolio in Q2 2026, its #210 holding.
- Baker Ellis Asset Management first reported a position in Edwards Lifesciences in Q4 2014 and has held it in 47 quarters since.
- Baker Ellis Asset Management's Edwards Lifesciences position peaked at $558K in Q4 2021.
- 1,327 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Baker Ellis Asset Management's 13F filing for Q2 2026, filed 23 Jul 2026.